ZURICH: Novartis AG is buying US biotechnology company The Medicines Co for about US$9.7bil, the Swiss drugmaker said, as it seeks to expand its portfolio of medicines against cardiovascular disease.
Novartis is paying US$85 per share in cash, about a 24% premium over The Medicines Co’s closing share price of US$68.55 last Friday.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
